Literature DB >> 20890893

Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis.

Christoph Roderburg1, Gerd-Willem Urban, Kira Bettermann, Mihael Vucur, Henning Zimmermann, Sabine Schmidt, Jörn Janssen, Christiane Koppe, Percy Knolle, Mirco Castoldi, Frank Tacke, Christian Trautwein, Tom Luedde.   

Abstract

UNLABELLED: Liver fibrosis is orchestrated by a complex network of signaling pathways regulating the deposition of extracellular matrix proteins during fibrogenesis. MicroRNAs (miRNAs) represent a family of small noncoding RNAs controlling translation and transcription of many genes. Recently, miRNAs have been suggested to crucially modulate cellular processes in the liver such as hepatocarcinogenesis. However, their role in liver fibrosis is not well understood. We systematically analyzed the regulation of miRNAs in a mouse model of carbon tetrachloride-induced hepatic fibrogenesis (CCl(4) ) by gene array analysis, which revealed a panel of miRNA that were specifically regulated in livers of mice undergoing hepatic fibrosis. Within those, all three members of the miR-29-family were significantly down-regulated in livers of CCl(4) -treated mice as well as in mice that underwent bile duct ligation. Specific regulation of miR-29 members in murine fibrosis models correlated with lower expression of miR-29 in livers from patients with advanced liver fibrosis. Moreover, patients with advanced liver cirrhosis showed significantly lower levels of miR-29a in their serum when compared with healthy controls or patients with early fibrosis. On a cellular level, down-regulation of miR-29 in murine hepatic stellate cells (HSCs) was mediated by transforming growth factor beta (TGF-β) as well as inflammatory signals, namely, lipopolysaccharide (LPS) and nuclear factor kappa B (NF-κB). Furthermore, overexpression of miR-29b in murine HSC resulted in down-regulation of collagen expression.
CONCLUSION: Our data indicate that miR-29 mediates the regulation of liver fibrosis and is part of a signaling nexus involving TGF-β- and NF-κB-dependent down-regulation of miR-29 family members in HSC with subsequent up-regulation of extracellular matrix genes. Thus they may represent targets for novel therapeutic strategies against hepatic fibrogenesis and also might evolve as biomarkers in the diagnosis of liver fibrosis.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890893     DOI: 10.1002/hep.23922

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  356 in total

1.  MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia.

Authors:  Nicholas J Hand; Amber M Horner; Zankhana R Master; LaTasha A Boateng; Claire LeGuen; Marina Uvaydova; Joshua R Friedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-02       Impact factor: 2.839

2.  Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma.

Authors:  Zehra Oksuz; Mehmet Sami Serin; Engin Kaplan; Aylin Dogen; Seda Tezcan; Gonul Aslan; Gurol Emekdas; Orhan Sezgin; Engin Altintas; Eyup Naci Tiftik
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

Review 3.  Targeting collagen expression in alcoholic liver disease.

Authors:  Kyle J Thompson; Iain H McKillop; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

4.  Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells.

Authors:  Jiang Li; Yifei Zhang; Ramalinga Kuruba; Xiang Gao; Chandrashekhar R Gandhi; Wen Xie; Song Li
Journal:  Mol Pharmacol       Date:  2011-04-21       Impact factor: 4.436

5.  Managing microvascular complications of diabetes with microRNAs.

Authors:  Shawn S Badal; Farhad R Danesh
Journal:  J Am Soc Nephrol       Date:  2012-01-12       Impact factor: 10.121

Review 6.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

7.  Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1.

Authors:  Chan Gyu Lee; Young Woo Kim; Eun Hyun Kim; Zhipeng Meng; Wendong Huang; Se Jin Hwang; Sang Geon Kim
Journal:  Gastroenterology       Date:  2012-01-18       Impact factor: 22.682

Review 8.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

Review 9.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

10.  NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6.

Authors:  Fujun Yu; Zhe Jiang; Bicheng Chen; Peihong Dong; Jianjian Zheng
Journal:  J Mol Med (Berl)       Date:  2017-09-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.